Search results for "ATP"

showing 10 items of 736 documents

Effects of controlled-release on the pharmacokinetics and absorption characteristics of a compound undergoing intestinal efflux in humans

2006

Abstract Objective The number of active pharmaceutical ingredients (API) undergoing inhibitable and saturable intestinal efflux is considerable. As a consequence, absorption and bioavailability may depend on the intestinal concentration profile of the drug and may vary as a function of dose and release rate of the drug from the dosage form. The impact of controlled versus immediate-release on the absorption of P-glycoprotein substrates is currently unknown. Thus, the main focus of the present study was a comparison of the pharmacokinetics of the P-gp model substrate talinolol following administration of immediate-release (IR) and controlled-release (CR) tablets to healthy human volunteers w…

AdultMaleActive ingredientChemistryPharmaceutical ScienceAbsorption (skin)PharmacologyCrossover studyControlled releaseDosage formBioavailabilityPropanolamineschemistry.chemical_compoundIntestinal AbsorptionSolubilityPharmacokineticsDelayed-Action PreparationsHumansFemaleATP Binding Cassette Transporter Subfamily B Member 1TabletsTalinololEuropean Journal of Pharmaceutical Sciences
researchProduct

Familial hemiplegic migraine type 2 is linked to 0.9Mb region on chromosome 1q23

2003

Familial hemiplegic migraine (FHM) is a rare autosomal dominant disorder characterized by episodes of transient hemiparesis followed by headache. Two chromosomal loci are associated to FHM: FHM1 on chromosome 19 and FHM2 on chromosome 1q21-23. Mutations of the alpha-1A subunit of the voltage gated calcium channel (CACNA1A) are responsible for FHM1. FHM2 critical region spans 28 cM, hence hampering the identification of the responsible gene. Here, we report the FHM2 locus refining by linkage analysis on two large Italian families affected by pure FHM. The new critical region covers a small area of 0.9Mb in 1q23 and renders feasible a positional candidate approach. By mutation analysis, we ex…

AdultMaleAdolescentGenetic LinkageMigraine with AuraLocus (genetics)Genetic determinismGenetic linkageATP1A2Chromosome 19HumansMedicineChildFamilial hemiplegic migraineAgedAged 80 and overGeneticsbusiness.industryChromosome MappingChromosomeMiddle Agedmedicine.diseasePedigreeNeurologyChromosomes Human Pair 1MutationMutation testingFemaleNeurology (clinical)Lod ScorebusinessNeuroscienceAnnals of Neurology
researchProduct

Correlation between GP-170 expression, prognosis, and chemoresistance of superficial bladder carcinoma.

2003

To study GP-170 in superficial bladder cancer at initial diagnosis and at recurrence and to evaluate if intravesical chemoprophylaxis modifies the expression of GP-170 in tumor recurrences. GP-170 was retrospectively assessed in 160 patients affected by primary superficial transitional cell carcinoma of the bladder and followed for up to 10 years. Eighty-four patients (52.5%) recurred after transurethral resection (TUR). Adjuvant intravesical chemotherapy after TUR was adopted in 52 patients. The correlations between GP-170 and G-grade, T-category, risk of recurrence and of progression, and adoption of adjuvant intravesical chemotherapy were investigated. The correlations between variations…

AdultMaleCancer Researchmedicine.medical_specialtyPathologymedicine.medical_treatmentUrologySettore MED/24 - UrologiaSuperficial bladder carcinoma GP-170 MDR-1 Prognosis Intravesical chemotherapyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineCarcinomaHumansATP Binding Cassette Transporter Subfamily B Member 1Stage (cooking)AgedRetrospective StudiesChemotherapyHematologyUrinary bladderbusiness.industryGeneral MedicineMiddle Agedmedicine.diseasePrognosisDrug Resistance MultipleGene Expression Regulation NeoplasticTransitional cell carcinomamedicine.anatomical_structureOncologyUrinary Bladder NeoplasmsChemotherapy AdjuvantDrug Resistance NeoplasmChemoprophylaxisFemaleSuperficial Bladder CarcinomaGenes MDRNeoplasm Recurrence LocalbusinessFollow-Up StudiesJournal of cancer research and clinical oncology
researchProduct

Effect of ouabain and furosemide on erythrocyte sodium and phosphate transport.

1981

The effects of ouabain and furosemide on the unidirectional efflux of sodium and phosphate ions were studied in freshly drawn human red blood cells (RBCs). In the presence of physiologic concentrations of sodium and potassium the rate of sodium efflux was reduced by 74% due to ouabain sensitivity. Furosemide (1.0 mmol/l) reduced ouabain-insensitive sodium transport rate by a further 50%. Thus, 13% of total sodium efflux was inhibited by furosemide when ouabain was present. In the absence of ouabain, however, furosemide inhibited 31% of total sodium transport, indicating that it also affected ouabain-sensitive sodium efflux. Phosphate transfer of RBCs was almost 1.0 mmol/l RBCs per hour. Ery…

AdultMaleCell Membrane PermeabilityErythrocytesPotassiumSodiumchemistry.chemical_elementBiological Transport ActiveOuabainIon ChannelsPhosphateschemistry.chemical_compoundHydrolysisFurosemidemedicineHumansPharmacology (medical)OuabainPharmacologyChromatographyChemistrySodiumFurosemidePhosphateBiochemistryPotassiumEffluxSodium-Potassium-Exchanging ATPaseAdenosine triphosphatemedicine.drugClinical pharmacology and therapeutics
researchProduct

Dietary polyunsaturated fatty acids may increase plasma LDL-cholesterol and plasma cholesterol concentrations in carriers of an ABCG1 gene single nuc…

2011

Abstract Background ABCG1 mediates cellular cholesterol transport, but there is very little known about the influence of ABCG1 polymorphisms on human plasma lipoprotein cholesterol concentrations or on the interactions of these polymorphisms with diet. Objective Our objective was to investigate whether interactions between PUFA intake and ABCG1 polymorphisms modulate associations with plasma total cholesterol (TC), LDL- and HDL-cholesterol in two Spanish populations. Methods We grounded our investigation on two general population-based studies: the Hortega study (population A) and the Pizarra study (population B). Participants included 1178 individuals (50.0% women, age range 21–85 years) a…

AdultMaleHeterozygotemedicine.medical_specialtyPopulationSingle-nucleotide polymorphismBiologyPolymorphism Single NucleotideYoung Adultchemistry.chemical_compoundGene FrequencySurveys and QuestionnairesInternal medicineGenotypemedicineHumansGene–environment interactionAlleleeducationAllele frequencyATP Binding Cassette Transporter Subfamily G Member 1AgedAged 80 and overchemistry.chemical_classificationGeneticseducation.field_of_studyChi-Square DistributionCholesterolHomozygoteCholesterol LDLMiddle AgedDietUp-RegulationCholesterolPhenotypeEndocrinologychemistrySpainFatty Acids UnsaturatedATP-Binding Cassette TransportersFemaleGene-Environment Interactionlipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicinePolyunsaturated fatty acidAtherosclerosis
researchProduct

Influence of ABCB1 polymorphisms upon the effectiveness of standard treatment for acute myeloid leukemia: A systematic review and meta-analysis of ob…

2015

The ABCB1 gene encodes for P-glycoprotein (P-gp), an efflux pump for a variety of xenobiotics. The role of ABCB1 polymorphisms in acute myeloid leukemia (AML) outcomes of standard chemotherapy (cytarabine plus anthracyclines) remains controversial. A systematic search was made of studies evaluating the association between ABCB1 polymorphisms 1236C>T, 2677G>T/A and 3435C>T and effectiveness variables. We found seven cohort studies (1241 patients) showing a significantly higher overall survival (OS) among carriers of the variant allele of 1236C>T at year 4 (odds ratio (OR): 1.47, 95% confidence interval (CI): 1.07-2.01), 2677G>T/A at years 4-5 (OR: 1.37, 95% CI: 1.01-1.86) and 3435C>T at year…

AdultMaleOncologymedicine.medical_specialtyATP Binding Cassette Transporter Subfamily BAdolescentSubgroup analysisCohort StudiesYoung AdultInternal medicineGeneticsmedicineHumansAnthracyclinesChildAgedAged 80 and overPharmacologyGeneticsPolymorphism Geneticbusiness.industryStandard treatmentCytarabineInfantMyeloid leukemiaOdds ratioMiddle AgedConfidence intervalLeukemia Myeloid AcuteObservational Studies as TopicTreatment OutcomeChild PreschoolMeta-analysisCytarabineMolecular MedicineFemalebusinessmedicine.drugCohort studyThe Pharmacogenomics Journal
researchProduct

Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: A multi-center, retrospective ana…

2014

Abstract Background Mitoxantrone is used on an off-label basis in primary progressive MS (PPMS). ABC -transporter-genotypes are associated with therapeutic response in relapsing/secondary progressive MS (RP/SPMS). Objective To evaluate potential pharmacogenetic response markers for mitoxantrone in PPMS. Methods 41 mitoxantrone-treated PPMS-patients, 155 mitoxantrone-treated RP/SPMS-patients and 43 PPMS-controls were retrospectively assessed for clinical therapy-response and in correlation with four single-nucleotide-polymorphisms in ABCB1 - and ABCG2 -genes. Results 53.7% PPMS-patients were mitoxantrone-responders, in comparison to 78.1% of RP/SPMS-patients (p = 0.039). There was no associa…

AdultMaleOncologymedicine.medical_specialtyTreatment responseATP Binding Cassette Transporter Subfamily Bmedicine.medical_treatmentImmunologyPrimary Progressive Multiple SclerosisPharmacologyInternal medicineGenotypeLack of efficacymedicineRetrospective analysisATP Binding Cassette Transporter Subfamily G Member 2HumansImmunology and AllergyRetrospective StudiesAnalgesicsMitoxantronebusiness.industryImmunosuppressionMiddle AgedMultiple Sclerosis Chronic ProgressiveNeoplasm Proteins3. Good healthNeurologyPharmacogeneticsATP-Binding Cassette TransportersFemaleNeurology (clinical)MitoxantronebusinessPharmacogeneticsmedicine.drugJournal of Neuroimmunology
researchProduct

Defects in the Human Leukocyte Antigen Class I Antigen Processing Machinery in Head and Neck Squamous Cell Carcinoma: Association with Clinical Outco…

2005

AbstractPurpose: Human leukocyte antigen (HLA) class I antigen defects, which are frequently present in head and neck squamous cell carcinoma (HNSCC) cells may provide the tumor with an escape mechanism from immune surveillance. Scanty information is available about mechanisms underlying HLA class I antigen defects in both lesions and cell lines from HNSCC. In this study, we investigate the role of antigen processing machinery (APM) component abnormalities in the generation of deficient HLA class I surface expression of HNSCC cells.Experimental Design: Using immunohistochemistry, Western blot, and RT-PCR analyses we correlated the expression of the IFN-γ inducible proteasome subunits and of…

AdultMaleProteasome Endopeptidase ComplexCancer ResearchPathologymedicine.medical_specialtyBlotting WesternDown-RegulationHuman leukocyte antigenBiologyCell LineInterferon-gammaATP Binding Cassette Transporter Subfamily B Member 3HLA AntigensMultienzyme ComplexesCell Line TumorTumor Cells Culturedotorhinolaryngologic diseasesmedicineCarcinomaHumansATP Binding Cassette Transporter Subfamily B Member 2AgedReverse Transcriptase Polymerase Chain ReactionAntigen processingHistocompatibility Antigens Class ICancerMiddle Agedmedicine.diseaseImmunohistochemistrySurvival AnalysisHead and neck squamous-cell carcinomaGene Expression Regulation NeoplasticCysteine Endopeptidasesstomatognathic diseasesOncologyHead and Neck NeoplasmsCarcinoma Squamous Cellbiology.proteinImmunohistochemistryTAP2ATP-Binding Cassette TransportersFemaleTAP1Clinical Cancer Research
researchProduct

Influence of CYP3A5 and ABCB1 gene polymorphisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients

2011

Tacrolimus is a substrate of cytochrome P4503A (CYP3A) enzymes as well as of the drug transporter ABCB1. We have investigated the possible influence of CYP3A5 and ABCB1 single nucleotide polymorphisms (SNPs) and other factors (e.g. albumin, hematocrit and steroids) on tacrolimus blood levels achieved in a population of Caucasian liver (n=51) and kidney (n=50) transplant recipients. At 1, 3 and 6 months after transplantation, tacrolimus doses (mg/kg/day) and trough blood levels (C0) were recorded and the weight-adjusted tacrolimus dosage (mg/kg/day) was calculated. Polymerase chain reaction followed by restriction fragment length polymorphism analysis was used for genotyping CYP3A5*1 and *3 …

AdultMalemedicine.medical_specialtyATP Binding Cassette Transporter Subfamily BGenotypemedicine.medical_treatmentDNA Mutational AnalysisPopulationSingle-nucleotide polymorphismLiver transplantationBiologyKidneyPolymorphism Single NucleotideGastroenterologyBiomarkers PharmacologicalTacrolimusWhite PeopleGene FrequencyInternal medicineGeneticsmedicineCytochrome P-450 CYP3AHumansDrug Dosage CalculationsATP Binding Cassette Transporter Subfamily B Member 1educationAllele frequencyAllelesKidney transplantationAgededucation.field_of_studyKidney metabolismGeneral MedicineMiddle Agedmedicine.diseaseKidney TransplantationTacrolimusLiver TransplantationTransplantationsurgical procedures operativeItalyLiverImmunologySettore BIO/14 - FarmacologiaPharmacogenetics CYP3A5 ABCB1 TacrolimusTransplant patientsFemaleImmunosuppressive AgentsPolymorphism Restriction Fragment LengthInternational Journal of Molecular Medicine
researchProduct

Role of Ca2+-activated K+ channels and Na+,K+-ATPase in prostaglandin E1- and E2-induced inhibition of the adrenergic response in human vas deferens

2011

We studied the role of K(+) channels and Na(+),K(+)-ATPase in the presynaptic inhibitory effects of prostaglandin E(1) (PGE(1)) and PGE(2) on the adrenergic responses of human vas deferens. Furthermore, we determined the effects of increasing extracellular K(+) concentrations ([K(+)](o)) and inhibition of Na(+),K(+)-ATPase on neurogenic and norepinephrine-induced contractile responses. Ring segments of the epididymal part of the vas deferens were taken from 45 elective vasectomies and mounted in organ baths for isometric recording of tension. The neuromodulatory effects of PGEs were tested in the presence of K(+) channel blockers. PGE(1) and PGE(2) (10(-8) to 10(-6)M) induced inhibition of …

AdultMalemedicine.medical_specialtyBioquímica clínicaAdrenergicApaminSynaptic TransmissionBiochemistryDinoprostoneOuabainPotassium Channels Calcium-Activatedchemistry.chemical_compoundOrgan Culture TechniquesVas DeferensInternal medicinePotassium Channel BlockersmedicineHumansAlprostadilNa+/K+-ATPasePharmacologyDose-Response Relationship DrugChemistryVas deferensPotassium channel blockerIberiotoxinElectric StimulationPotassium channelReceptors AdrenergicEndocrinologymedicine.anatomical_structurelipids (amino acids peptides and proteins)Sodium-Potassium-Exchanging ATPaseMuscle Contractionmedicine.drugBiochemical Pharmacology
researchProduct